[go: up one dir, main page]

BRPI0520129A2 - uso de 5'-metiltioadenosina (mta) na prevenÇço e/ou no tratamento de doenÇas auto-imunes e/ou rejeiÇço de transplante - Google Patents

uso de 5'-metiltioadenosina (mta) na prevenÇço e/ou no tratamento de doenÇas auto-imunes e/ou rejeiÇço de transplante

Info

Publication number
BRPI0520129A2
BRPI0520129A2 BRPI0520129-2A BRPI0520129A BRPI0520129A2 BR PI0520129 A2 BRPI0520129 A2 BR PI0520129A2 BR PI0520129 A BRPI0520129 A BR PI0520129A BR PI0520129 A2 BRPI0520129 A2 BR PI0520129A2
Authority
BR
Brazil
Prior art keywords
prevention
treatment
methylthioadenosine
mta
autoimmune diseases
Prior art date
Application number
BRPI0520129-2A
Other languages
English (en)
Inventor
Pablo Villoslada Diaz
Matias Avila Zaragoza
Beatriz Moreno Bruna
Fernando Corrales Izquierdo
Carmen Berasain Lasarte
Elena Ruiz Garcia-Trevijano
Original Assignee
Proyecto Biomedicina Cima Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto Biomedicina Cima Sl filed Critical Proyecto Biomedicina Cima Sl
Publication of BRPI0520129A2 publication Critical patent/BRPI0520129A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

USO DE 5'-METILTIOADENOSINA (MTA) NA PREVENÇçO E/OU NO TRATAMENTO DE DOENÇAS AUTO-IMUNES E/OU REJEIÇçO DE TRANSPLANTE. 5'-metiltioadenosina (MTA), seus sais farmaceuticamento aceitáveis e/ou pró-drogas podem ser usados na prevenção e/ou no tratamento de doenças auto-imunes, como, por exemplo, Esclerose Múltipla (MS), como também na prevenção e/ou no tratamento de rejeição de transplante.
BRPI0520129-2A 2005-03-17 2005-03-17 uso de 5'-metiltioadenosina (mta) na prevenÇço e/ou no tratamento de doenÇas auto-imunes e/ou rejeiÇço de transplante BRPI0520129A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/ES2005/000139 WO2006097547A1 (es) 2005-03-17 2005-03-17 Empleo de 5'-metiltioadenosina (mta) en la prevención y/o tratamiento de enfermedades autoinmunes y/o rechazo de transplantes

Publications (1)

Publication Number Publication Date
BRPI0520129A2 true BRPI0520129A2 (pt) 2009-04-28

Family

ID=36991307

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0520129-2A BRPI0520129A2 (pt) 2005-03-17 2005-03-17 uso de 5'-metiltioadenosina (mta) na prevenÇço e/ou no tratamento de doenÇas auto-imunes e/ou rejeiÇço de transplante

Country Status (19)

Country Link
US (1) US7820637B2 (pt)
EP (1) EP1891961B1 (pt)
JP (1) JP2008533107A (pt)
CN (1) CN101141970A (pt)
AT (1) ATE442854T1 (pt)
AU (1) AU2005329287B2 (pt)
BR (1) BRPI0520129A2 (pt)
CA (1) CA2601557A1 (pt)
CY (1) CY1109539T1 (pt)
DE (1) DE602005016729D1 (pt)
DK (1) DK1891961T3 (pt)
ES (1) ES2334924T3 (pt)
HR (1) HRP20090646T1 (pt)
MX (1) MX2007011327A (pt)
PL (1) PL1891961T3 (pt)
PT (1) PT1891961E (pt)
RS (1) RS51122B (pt)
SI (1) SI1891961T1 (pt)
WO (1) WO2006097547A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2329327B1 (es) 2008-03-19 2010-09-17 Proyecto De Biomedicina Cima, S.L. Combinaciones sinergicas de 5'-metiltioadenosina.
EP2441459A1 (en) * 2009-06-11 2012-04-18 Proyecto de Biomedicina Cima, S.L. 5'-methylthioadenosine neuroprotective properties
WO2011054990A2 (es) * 2009-11-05 2011-05-12 Proyecto De Biomedicina Cima, S.L. Composiciones para la inhibición y/o bloqueo de la transición epitelial-mesenquimal
JP5801572B2 (ja) * 2011-03-03 2015-10-28 シーシーアイ株式会社 ＰＰＡＲγ活性化剤
CN105125571B (zh) * 2015-07-17 2018-11-06 四川大学 Prmt1抑制剂在制备治疗可卡因成瘾的药物中的用途
WO2020206289A1 (en) * 2019-04-05 2020-10-08 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5
WO2020206299A1 (en) 2019-04-05 2020-10-08 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5
CN114515294A (zh) 2022-02-25 2022-05-20 浙江中医药大学 5’-甲基硫代腺苷在制备肥胖抑制药物或保健品中的应用
CN117122689A (zh) * 2023-09-12 2023-11-28 四川省医学科学院·四川省人民医院 Mta在制备治疗急性葡萄膜炎药物中的应用
CN118141910B (zh) * 2024-04-03 2025-10-28 河北医科大学 甲基转移酶抑制剂作为呼吸道合胞病毒疫苗及过敏疫苗佐剂的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1193529B (it) * 1980-04-22 1988-07-08 Bioresearch Srl Derivati adenosinici ad attivita' antinfiammatoria ed analgesica e composizioni terapeutiche che li contengono come principio attivo
IT1227049B (it) 1988-07-29 1991-03-14 Bioresearch Spa Impiego di derivati adenosinici per la preparazione di composizioni farmaceutiche aventi attivita' immunostimolante.
JP2001524936A (ja) * 1996-10-16 2001-12-04 アイ・シー・エヌ・フアーマシユーテイカルズ・インコーポレイテツド プリンｌ―ヌクレオシド類およびその用途
ES2237850T3 (es) * 1997-10-14 2005-08-01 Mitsubishi Pharma Corporation Compuestos de piperazina y su uso medicinal.
TW466112B (en) * 1998-04-14 2001-12-01 Lilly Co Eli Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same
JP2001072660A (ja) * 1999-09-08 2001-03-21 Welfide Corp ＴＮＦ−α産生抑制剤および／またはＩＬ−１０産生促進剤
TR200402292T4 (tr) * 2000-01-31 2004-12-21 Pfizer Products Inc. PDE4 izozimlerinin inhibitörleri olarak pirimidin karboksamidler.
WO2001066518A1 (en) * 2000-03-09 2001-09-13 Ono Pharmaceutical Co., Ltd. φ-SUBSTITUTED PHENYL-PROSTAGLANDIN E-ALCOHOLS, PROCESS FOR PRODUCING THE SAME AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
WO2003028712A2 (en) 2001-09-28 2003-04-10 Universite Libre De Bruxelles Purinergic and pyrimidinergic receptor agonists for the treatment of activated cd4+ t lymphocyte-mediated immune diseases
DE10207843A1 (de) * 2002-02-15 2003-09-04 Schering Ag Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen
IL148736A0 (en) * 2002-03-18 2002-09-12 Pharmos Corp Dexanabinol and dexanabinol analogs which regulate inflammation related genes

Also Published As

Publication number Publication date
DK1891961T3 (da) 2009-12-21
EP1891961A1 (en) 2008-02-27
JP2008533107A (ja) 2008-08-21
US20090042831A1 (en) 2009-02-12
SI1891961T1 (sl) 2010-01-29
PT1891961E (pt) 2009-12-17
HRP20090646T1 (hr) 2010-01-31
PL1891961T3 (pl) 2010-02-26
ES2334924T3 (es) 2010-03-17
CY1109539T1 (el) 2014-08-13
CA2601557A1 (en) 2006-09-21
EP1891961B1 (en) 2009-09-16
MX2007011327A (es) 2008-01-28
ATE442854T1 (de) 2009-10-15
WO2006097547A1 (es) 2006-09-21
AU2005329287B2 (en) 2011-01-27
DE602005016729D1 (de) 2009-10-29
AU2005329287A1 (en) 2006-09-21
US7820637B2 (en) 2010-10-26
RS51122B (sr) 2010-10-31
CN101141970A (zh) 2008-03-12

Similar Documents

Publication Publication Date Title
CY1109539T1 (el) Χρηση 5'-μεθυλοθειοαδενοσινης (μτα) στην προληψη και/η θεραπεια αυτοανοσων νοσων και/η απορριψης μοσχευματων
BR0311285A (pt) composições e processos para revestimento de implantes médicos
MY144318A (en) Methods of treating hiv infection.
WO2002064096A3 (en) Methods of using pyrimidine-based antiviral agents
PT1560812E (pt) Compostos de aminociclohexil eter e suas utilizacoes
DK1594833T3 (da) 1-phenylalkancarboxylsyrederivater til behandling af neurodegenerative sygdomme
PA8583601A1 (es) Derivados de pirrolidona como inhibidores de maob
ATE534391T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
DE60313004D1 (de) Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination
IL181909A0 (en) Phosphoindoles as hiv inhibitors
WO2006034001A3 (en) Methods of treating hiv infection
WO2007059226A3 (en) Photoactivatable antimicrobial agents
DE602004014787D1 (de) Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln
DE60041198D1 (de) Antimikrobielle zusammensetzungen
BRPI0509667A (pt) azaquinazolinas substituìdas com eficácia antiviral
WO2005002570A8 (en) Use of an aziridino compound to selectively inactivate parasites in biological compositions
BR0002640A (pt) Uso de simeticona para tratar colite ulcerativa
SE0004098D0 (sv) Novel compounds
WO2007081365A3 (en) Multiple antigenic agents and methods for using the same
ATE306940T1 (de) Zusammensetzung gegen coccidiose
WO2005048715A3 (de) Phosphororganische verbindungen und deren verwendung
PL1865961T3 (pl) Famciklowir do leczenia nawracającej opryszczki wargowej z zastosowaniem leczenia jednodniowego
SI1656372T1 (sl) Spojine 2,4-pirimidindiamina za uporabo pri zdravljenju ali preventivi avtoimunih bolezni

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE A DESPACHO 8.6 NA RPI 2160 DE 29/05/2012.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]